January 7, 2019
Axsome Therapeutics’ AXS-05 nvestigational drug meets endpoint in Phase 2 trial in major depressive disorder
Axsome Therapeutics’ AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the prespecified primary endpoint and significantly improved symptoms of depression in the ASCEND Phase 2 trial in major depressive disorder (MDD), the company said Monday.